Glycomed

Glycomed was a pioneering biotechnology company focused on the field of glycobiology, specifically the development of carbohydrate-based therapeutics. Founded in 1987 and based in Alameda, California, the company specialized in identifying and developing drugs that modulate the activity of cell-surface carbohydrates and their receptors. Its research targeted a variety of conditions, including inflammatory diseases, cancer, and cardiovascular disorders. Glycomed's pipeline included selectin inhibitors and heparin-like compounds designed to prevent cell adhesion and thrombosis. The company was publicly traded on the NASDAQ under the symbol GLYC until its acquisition by Ligand Pharmaceuticals in 1995.